Stoichiometric "Locked Lesions": Does MLH1-Specific Atrophy Convert MSH2 into a Genomic Roadblock in Post-Mitotic Tissues?
The Mismatch Repair Asymmetry
Recent data from hematopoietic progenitor cells (HPCs) shows a strange split in how the Mismatch Repair (MMR) system ages: MSH2 expression stays remarkably stable, but MLH1 gets silenced via CpG promoter methylation as we age [PMC3476537]. This shift drives a measurable rise in micro-satellite instability (MSI-H) at a rate of roughly 0.16% per year [PMC3476537]. Most researchers have treated this as a simple "loss of function" story, but I suspect we're missing a more destructive "stoichiometric toxicity" happening under the surface.
The "Orphaned MutS" Hypothesis
My hypothesis is that losing MLH1 doesn't just result in a passive failure to fix DNA; it turns the remaining MSH2 protein into a physical roadblock. In a healthy cell, MSH2-MSH6 (MutSα) or MSH2-MSH3 (MutSβ) heterodimers find a mismatch and then recruit the MLH1-PMS2 (MutLα) complex to start the repair and clear the site.
In an aging cell where MLH1 is gone, these MutS complexes can still find and bind DNA, but they lack the partner they need to finish the cycle and let go. This creates "Locked Lesions"—orphaned MSH2 heterodimers that sit stalled on mismatches or oxidative damage like 8-oxoG. These complexes physically block the site, preventing other systems like Base Excision Repair (BER) or high-fidelity polymerases from getting to the DNA.
Mechanistic Implications and Mitochondrial Cross-talk
This "roadblock" model helps explain why MLH1 deficiency seems to trigger mitochondrial trouble and a spike in ROS [PMC8495402]. We know MSH2 plays a role in repairing oxidative damage [PMC8495402], so if it’s stable but orphaned, it likely binds to mitochondrial DNA (mtDNA) lesions and stalls transcription or replication. This would tank respiratory efficiency. The resulting ROS surge could then act as a signal that further drives MLH1 promoter methylation, creating a feed-forward loop that accelerates the slide into an MSI-H phenotype [16098563].
Testable Predictions
To see if this holds up, we need to look beyond the blood-derived cells that most of the literature focuses on [16098563].
- ChIP-seq Analysis of Occupancy: In older primary tissues like neurons or cardiomyocytes, we should find a relative increase in MSH2-DNA occupancy at mismatch-prone sites where MLH1 levels have dropped.
- Stoichiometric Correction: If we knock down MSH2 in MLH1-deficient aging cells, it might actually improve certain markers—like transcriptional elongation rates—by clearing out these proteinaceous hurdles, even if the mutation rate stays high.
- Tissue-Specific Kinetics: I predict that post-mitotic tissues like the brain will show slower MLH1 methylation than HPCs, but they’ll be far more sensitive to these "Locked Lesions" because they can't dilute the stalled complexes through cell division.
Challenging the Bystander Narrative
If this hypothesis is correct, MMR failure isn't just a bystander that allows mutations to accumulate; it's a physical disruptor of the genome. When MLH1 disappears, the stable MSH2 protein essentially acts as an anchor for damage, ensuring "epigenetic scars" never get the chance to heal. We aren't just looking at the loss of a repair system, but the active creation of inhibitory nucleoprotein complexes that drive the aging phenotype.